Ryan Wilcox, MD, PhD

Trials

Studies that name Ryan Wilcox, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:35 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04858256 · Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

  University of Michigan Rogel Cancer Center · recruiting · T-Cell Neoplasm, Lymphoproliferative Disorders · principal investigator
• Ph2
  NCT03927105 · Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

  University of Michigan Rogel Cancer Center · completed · Peripheral T Cell Lymphoma · principal investigator
• Ph1
  NCT03601819 · Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

  University of Michigan Rogel Cancer Center · terminated · Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia · principal investigator
• Ph1/Ph2
  NCT03547700 · Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

  University of Michigan Rogel Cancer Center · terminated · Lymphoma, T-Cell, Peripheral · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Pacritinib in rel/refr T-cell lymphomas
  R01CA265929 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ryan A Wilcox · fiscal years 2021 to 2025
  Named on NCT04858256